Novavax, Inc. $NVAX Shares Purchased by First Trust Advisors LP

First Trust Advisors LP raised its holdings in Novavax, Inc. (NASDAQ:NVAX) by 37.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 409,328 shares of the biopharmaceutical company’s stock after acquiring an additional 112,009 shares during the quarter. First Trust Advisors LP owned 0.25% of Novavax worth $3,332,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in NVAX. State Street Corp boosted its holdings in Novavax by 32.3% during the fourth quarter. State Street Corp now owns 9,523,646 shares of the biopharmaceutical company’s stock worth $63,999,000 after buying an additional 2,326,927 shares in the last quarter. UBS Group AG increased its holdings in Novavax by 40.3% in the fourth quarter. UBS Group AG now owns 4,894,284 shares of the biopharmaceutical company’s stock valued at $32,890,000 after buying an additional 1,405,981 shares in the last quarter. Monaco Asset Management SAM increased its holdings in Novavax by 161.3% in the fourth quarter. Monaco Asset Management SAM now owns 1,045,000 shares of the biopharmaceutical company’s stock valued at $7,022,000 after buying an additional 645,000 shares in the last quarter. Barclays PLC boosted its stake in shares of Novavax by 108.8% during the 4th quarter. Barclays PLC now owns 1,102,300 shares of the biopharmaceutical company’s stock worth $7,407,000 after acquiring an additional 574,263 shares in the last quarter. Finally, Jump Financial LLC acquired a new stake in shares of Novavax in the 3rd quarter worth approximately $3,874,000. 53.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on NVAX. B. Riley Financial reaffirmed a “buy” rating on shares of Novavax in a research note on Thursday, April 9th. Wall Street Zen cut Novavax from a “hold” rating to a “sell” rating in a research report on Saturday, August 1st. Zacks Research upgraded shares of Novavax from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 6th. BTIG Research reissued a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research note on Thursday, June 11th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Novavax in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Novavax currently has a consensus rating of “Hold” and a consensus target price of $13.00.

Novavax Price Performance

NASDAQ:NVAX opened at $7.74 on Friday. The firm has a market cap of $1.27 billion, a PE ratio of -13.34 and a beta of 2.46. The firm has a 50 day simple moving average of $8.79 and a 200-day simple moving average of $8.98. Novavax, Inc. has a 1-year low of $6.20 and a 1-year high of $11.97.

Novavax (NASDAQ:NVAX) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.06. The firm had revenue of $56.70 million for the quarter, compared to analysts’ expectations of $52.51 million. Novavax had a negative return on equity of 14.82% and a negative net margin of 14.73%.The firm’s revenue for the quarter was down 76.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.62 earnings per share. As a group, sell-side analysts expect that Novavax, Inc. will post -0.19 earnings per share for the current fiscal year.

Key Headlines Impacting Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax reported second-quarter revenue of $56.7 million, exceeding the approximately $52.5 million consensus estimate, while its adjusted loss of $0.32 per share was narrower than analysts expected. Novavax Q2 earnings report
• Positive Sentiment: The company increased its full-year 2026 adjusted revenue framework to $235 million–$275 million from $230 million–$270 million, supported by licensing and milestone-related revenue. Novavax raises 2026 revenue outlook after Q2 beat
• Positive Sentiment: Novavax improved its combined GAAP research and development plus selling, general and administrative expense guidance by $10 million at the midpoint, reinforcing its cost-reduction strategy. It ended June with approximately $724 million in cash, cash equivalents, marketable securities, and restricted cash. Novavax second-quarter financial results
• Positive Sentiment: Sanofi’s collaboration remains a key potential catalyst: manufacturing technology transfer is expected to finish in mid-2027, which would trigger a $75 million milestone payment. Sanofi also plans to advance discussions with regulators on a Phase 3 COVID-19/influenza combination vaccine trial. Novavax lifts annual revenue forecast
• Neutral Sentiment: Management is increasingly focused on licensing its Matrix-M adjuvant and developing additional programs, including a potential C. difficile vaccine entering clinical development as early as 2027. These opportunities could diversify revenue but remain long-term and execution-dependent. Novavax Q2 2026 earnings call transcript
• Negative Sentiment: Revenue declined 76% year over year to $56.7 million, and Novavax posted a $53 million net loss versus $107 million of net income in the prior-year quarter. The results highlight the company’s continuing dependence on partnership payments as COVID-19 vaccine demand weakens. Novavax Q2 revenue falls 76 percent

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.